25 results about "Invasion and migration" patented technology

The invention provides a bacterial outer membrane vesicle presenting Stoppin peptide as well as a construction method and application of the bacterial outer membrane vesicle, and relates to the technical field of biological medicines. According to the invention, a fusion protein ClyA-Stoppin is firstly designed and synthesized, and the fusion protein ClyA-Stoppin is displayed on the surface of the bacterial outer membrane vesicle by using a genetic engineering technology, so that the engineered bacterial outer membrane vesicle W-Stoppin OMV for targeting presentation of Stoppin peptide is successfully constructed. The W-Stoppin OMV provided by the invention has a remarkable inhibition effect on invasion and migration of tumor cells and can be used for remarkably promoting apoptosis of the tumor cells. According to the present invention, with the Stoppin monopeptide, the problems of insufficient Stoppin cell penetrability and difficult intracellular delivery are effectively solved, compared with the Stoppin monopeptide, the Stoppin monopeptide shows the excellent anti-tumor effect, and the migration inhibition, the invasion inhibition and the apoptosis promotion effects on the tumor cells are significantly increased. The W-Stoppin OMV provided by the invention has huge application potential in the aspect of preparation of anti-tumor drugs.

The application specifically relates to a breast cancer invasion and metastasis model based on anisotropic collagen hydrogel and a construction method thereof, and belongs to the technical field of biomedical materials and tumor microenvironment. The anisotropic hydrogel with highly parallel arrangement of collagen fibers is prepared by adopting a PDMS mold pre-tensioning-stress rebound process, and the orientation index is 0.62+ / -0.05. The hydrogel has high matching of mechanical properties with the breast cancer microenvironment in vivo and good biocompatibility. The model can induce mature adipocytes to dedifferentiate and fibroblasts to transdifferentiate, and drive the breast cancer cells to have enhanced invasion and migration ability and EMT phenotype, and reproduce a pathological axis of "collagen orientation→adipocyte dedifferentiation→breast cancer invasion and metastasis". The process depends on the activation of a DDR1-integrin beta1-FAK-YAP signal path, and a DDR1 inhibitor can effectively reverse the above effects. The application can be used for breast cancer metastasis mechanism research and drug screening targeting the DDR1 path.

The invention relates to application of (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium in preparation of anti-cancer drugs, and belongs to the technical field of medical application, the structure of (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium is as shown in the following formula I, the (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium can inhibit the growth of gastric cancer cells, inhibit the proliferation, invasion and migration of the gastric cancer cells by promoting the autophagy and mitochondrial rupture of AGS and HGC-27 cells of the gastric cancer cells, and block the gastric cancer cells in the G1 stage. Furthermore, in-vivo experiments of mice prove that ZWK-3 can inhibit tumor growth of the mice, shows obvious dose dependence, and does not influence the body weight and visceral indexes of the mice at the same time. Formula I.

The application belongs to the field of medicine, and particularly relates to application of CZC-54252 in preparation of a drug for treating esophageal squamous cell carcinoma. The results of the application show that CZC-54252 can efficiently inhibit expression of RSK4 enzyme, and can efficiently inhibit proliferation, invasion and migration of esophageal squamous cell carcinoma cells. In combination with Afatinib, the proliferation of an esophageal squamous cell carcinoma erlotinib-resistant strain can be significantly inhibited, and the results provide an effective technical means for treatment and prognosis of esophageal squamous cell carcinoma patients.

The invention discloses application of a lipid synthesis inhibitor in treatment of breast cancer. Researches prove that F.n colonization exists in breast cancer tissues, and the F.n can regulate and control lipid deposition related gene expression and lipid metabolism change of tumor-related macrophages, so that lipid deposition of the macrophages and proliferation, invasion and migration capabilities of tumor cells are promoted; after the lipid deposition inhibitor is added, the lipid metabolism disorder of the tumor-associated macrophages can be inhibited, the tumor malignant phenotype is finally inhibited, and the treatment of the breast cancer is realized. The invention provides a new potential therapeutic target and a new therapeutic drug for effective treatment of breast cancer.

The application discloses poplar phellinus polysaccharide SVP-1, a preparation method and application thereof, and belongs to the field of biological medicines. The poplar phellinus polysaccharide SVP-1 provided by the application has significant antitumor activity, can effectively inhibit the proliferation, invasion and migration of tumor cells, and thus blocks the malignant progression of tumors. The structure is clear, the preparation method is controllable, the stability and biological activity of the polysaccharide component are ensured, and a reliable foundation is provided for the development of antitumor drugs. The combination with radiotherapy and chemotherapy drugs can play a synergistic effect, can not only improve the sensitivity of tumors to treatment, but also reduce the toxic and side effects of radiotherapy and chemotherapy, and realizes the effect of 'attenuation and synergism'. The combined treatment strategy can significantly improve the curative effect of the existing tumor therapy, while reducing the adverse reactions, and provides a new optimization scheme for clinical tumor treatment.

The invention provides a novel human distal bile duct cancer cell line with TP53 missense mutation and application, the novel human distal bile duct cancer cell line CBC3T-3 is established, the cell line is preserved in the China Center for Type Culture Collection (the preservation number is CCTCC NO: C202555), the uniqueness and stability of the cell line are proved through STR typing and karyotype analysis, and the TP53 missense mutation novel human distal bile duct cancer cell line has the advantages that the TP53 missense mutation novel human distal bile duct cancer cell line CBC3T-3 can be used for preparing the TP53 missense mutation novel human distal bile duct cancer cell line CBC3T-3; and a plurality of driver gene mutations including TP53 missense mutation are carried. The CBC3T-3 has strong proliferation, invasion and migration capabilities, has high tumor formation rate in immunodeficient mice, is resistant to cis-platinum and sensitive to paclitaxel and gemcitabine, and provides an experimental basis for selection of clinical chemotherapy regimens. According to the model, the TP53 missense mutation type distal bile duct cancer in-vitro model is successfully established, and a key experimental platform is provided for deeply researching the drug resistance mechanism of the TP53 missense mutation type distal bile duct cancer and developing an individualized treatment strategy aiming at the subtype of the TP53 missense mutation type distal bile duct cancer.

The application discloses application of a traditional Chinese medicine gecko microRNA in preparation of an anti-tumor metastasis treatment drug. Through extensive and in-depth research, the application discloses that the gecko-miR-2862 mimic can inhibit invasion and migration of liver cancer cells through a scratch test and a Transwell test; the gecko-miR-2862 mimic is transfected into cancer cells to first disclose that the gecko-miR-2862 mimic can target and inhibit mRNA of a cancer gene SRC in the cancer cells and protein expression of genes related to the SRC signal path, and further discloses the treatment effect of the gecko-miR-2862 mimic on tumor metastasis. The application provides a direction and a technical basis for research and development of a new drug for resisting tumor metastasis treatment, and further develops a new traditional Chinese medicine gecko microRNA as an anti-tumor metastasis treatment drug.

The application discloses application of a PI3K-gamma-delta signal path inhibitor in preparation of a product for treating central nervous system leukemia and the product, and solves the technical problem that the prior art lacks a molecular targeting product for acute lymphoblastic leukemia with CNSL which has better effect. The application comprises: application of the PI3K-gamma-delta signal path inhibitor in preparation of a product for treating acute lymphoblastic leukemia with central nervous system leukemia, and application of the PI3K-gamma-delta signal path inhibitor in preparation of a product for inhibiting proliferation, invasion and migration of acute lymphoblastic leukemia with central nervous system leukemia. The application also comprises a product of the PI3K-gamma-delta signal path inhibitor. The application discloses that central nervous system leukemia is closely related to an expression level of MSLN, and the PI3K-gamma-delta signal path inhibitor can inhibit the infiltration degree of acute lymphoblastic leukemia with central nervous system leukemia by reducing the expression level of MSLN, and prolong the survival time.

The invention discloses a method for regulating and controlling tumor invasion and migration ability through a TGF-betaSmad7 signal by using MYL9 as a marker, which is characterized by comprising the following steps: (1) culturing kidney cancer cells in a DMEM (Dulbecco Modified Eagle Medium) added with 10% fetal calf serum; (2) carrying out gene silencing by using a HiPerFect transfection reagent, specifically knocking down the expression of MYL9, and regulating and controlling a TGF-beta1 / Smad7 signal channel; and (3) detecting the migration and invasion ability of the kidney cancer cells by adopting a Transwell experiment, adding 200 mu L of DMEM containing 0.5% of FBS into the upper hole, adding 600 mu L of DMEM containing 10% of FBS into the lower hole, and filling the kidney cancer cells treated in the step (2) for a migration and invasion experiment. MYL9 is connected with matrix mechanics, angiogenesis and immune escape through a TGF-beta / Smad7 signal axis, and by regulating and controlling the TGF-beta Smad7 signal, the invasion ability of kidney cancer cells can be effectively reduced, the traditional cognition of single-dimensional regulation and control on a kidney cancer microenvironment is broken through, and a multi-dimensional perspective is provided for understanding tumor progression.

The invention discloses application of a substance for inhibiting polyamine synthesis in preparation of a medicine for treating or relieving endometrial cancer. According to experimental verification of an endometrial cancer cell model and an animal model, it is found that high-fat culture promotes rise of endometrial cancer cell ODC1 and accumulation of polyamine metabolites; mouse serum polyamine metabolites can be up-regulated by feeding the bilateral ovariectomy mouse with high fat; oA-induced polyamine metabolite accumulation and invasion and migration of endometrial cancer cells can be inhibited by knocking down the ODC1; in an animal model, ODC1 is knocked out, and transplantation tumor growth and lymph node metastasis promoted by high fat can also be inhibited by applying an ODC1 inhibitor DFMO. The DFMO can improve the sensitivity of endometrial cancer patients which are resistant to chemotherapeutic drugs. The invention finds that the serum polyamine can be used as a target for developing a medicine for treating or relieving endometrial cancer, and can also be used as a marker for grouping endometrial cancer patients of mammals.

The application discloses application of circular RNA Hsa_circ_0006332 in diagnosis and treatment of esophageal squamous cell carcinoma and belongs to the field of biological medicine. The application comprises application of a reagent capable of detecting Hsa_circ_0006332 or an expression amount thereof in preparation of a kit for diagnosing esophageal squamous cell carcinoma, wherein the Hsa_circ_0006332 nucleotide sequence is SEQ ID NO. 1. The application also comprises application of a component capable of inhibiting or blocking expression of Hsa_circ_0006332 in preparation of a medicine for treating esophageal squamous cell carcinoma. The application changes an expression level of Hsa_circ_0006332 in esophageal squamous cell carcinoma cells through construction of Hsa_circ_0006332 specific siRNAs and other molecular biology means, reveals that interference with Hsa_circ_000632 expression can significantly inhibit esophageal squamous cell carcinoma cell proliferation, invasion and migration, promote cancer cell apoptosis and other tumor cell biological phenotypes. Therefore, Hsa_circ_0006332 can be used as a treatment target in preparation, screening or treatment of esophageal squamous cell carcinoma or medicines for inhibiting migration and invasion of esophageal squamous cell carcinoma, and provides a new treatment method for intervention or treatment of esophageal squamous cell carcinoma.

The application provides application of indole acetic acid in intervention or treatment of thyroid cancer caused by long-term low-dose ionizing radiation, and belongs to the field of biomedical technology. It is found that indole acetic acid (IAA) is significantly negatively correlated with the occurrence of thyroid nodules after low-dose radiation, the proliferation, clone formation, invasion and migration of BCPAP cells can be inhibited after IAA is supplemented, and the tumor formation ability is greatly reduced, so the thyroid cancer caused by long-term low-dose ionizing radiation can be treated by supplementing IAA. The application also screens the KCNE4 gene for regulating the thyroid cancer caused by long-term low-dose ionizing radiation, and IAA can inhibit the expression of the gene, which indicates that IAA and the inhibitor of the gene both have the potential of serving as a therapeutic target for the thyroid cancer caused by long-term low-dose ionizing radiation.

The invention relates to an application of miR-6742-5p (micro Ribonucleic Acid-6742-5p) in preparation of an anti-liver cancer product. The nucleotide sequence of the miR-6742-5p is as shown in SEQ ID NO. 1 (sequence identifier number 1). Experiments prove that proliferation, invasion and migration of liver cancer cells can be effectively inhibited by overexpression of miR-6742-5p, malignant progression of tumors can be predicted by detecting the expression level of miR-6742-5p, and therefore the miR-6742-5p has potential application value in the aspect of treatment of malignant tumors such as liver cancer.

The invention discloses a polypeptide for inhibiting lung adenocarcinoma metastasis and application thereof, belongs to the technical field of biology, and aims to solve the problems that lung adenocarcinoma cells in the prior art have very strong invasion and migration ability, and non-small cell lung cancer patients with high expression of NSUN2 easily generate drug resistance to gefitinib drugs. The amino acid sequence of the polypeptide for inhibiting lung adenocarcinoma metastasis is as shown in a general formula X-RHTQIRPTMFPPY; x at the N terminal in the general formula represents a modification group, and Y at the tail represents a cell-penetrating peptide; the invention is suitable for preparing a therapeutic reagent for lung cancer, and can achieve the effect of inhibiting the methylation modification of NSUN2 so as to inhibit the metastasis of lung adenocarcinoma.

The application provides application of VPS53 in intervention target of thyroid cancer caused by long-term low-dose ionizing radiation, and belongs to the technical field of biological medicine.The application takes VPS53 as the intervention target of thyroid cancer caused by long-term low-dose ionizing radiation, finds that the copy number of VPS53 gene increases after long-term low-dose irradiation, and the expression level of VPS53 increases.In the thyroid cancer cell line with high expression of VPS53, the expression of VPS53 is knocked down, the proliferation, migration and invasion ability is weakened, the tumor volume is smaller, and the tumor grows more slowly;in the thyroid cancer cell line with low expression of VPS53, the expression of VPS53 is overexpressed, the proliferation, invasion and migration ability is enhanced, the tumor volume is larger, and the tumor grows faster.The application proves that knocking down VPS53 is a candidate intervention target of the occurrence and development of thyroid cancer caused by long-term low-dose ionizing radiation.

The application discloses a use of a HOTAIR-PRC2 blocking agent combined with a progestogen in preparation of a drug for conservation treatment of endometrial cancer. The application provides a use of a HOTAIR-PRC2 specific blocking agent combined with a progestogen, which can synergistically inhibit the progression of endometrial cancer. The HOTAIR-PRC2 specific blocking agent provided by the application can restore the expression of PR, and the combination of the progestogen can synergistically inhibit the proliferation, invasion and migration of tumors, promote cell apoptosis, block the cell cycle, and enhance the treatment effect of the progestogen, thereby providing a new treatment idea for the conservation treatment of endometrial cancer.

The invention relates to the technical field of medicines, in particular to application of actinomycin V in preparation of a medicine for treating chronic myelogenous leukemia. In the aspect of cell function, the Act-V shows comprehensive anti-CML activity, not only can inhibit K562 cell proliferation in a time and dose dependent manner, but also can effectively inhibit colony forming ability, reduce the number and diameter of formed tumor spheres and lower the sphere forming frequency. Experiments prove that the Act-V further weakens the dry characteristics of tumors by down-regulating the expression of dry markers such as CD133, CD44, ALDH1A1 and the like. Besides, the Act-V can significantly inhibit the invasion and migration ability of CML cells, and western blot experiment results prove that the Act-V down-regulates the expression of interstitial markers N-Cadherin and Vimentin, up-regulates the expression of an epithelial marker E-Cadherin and inhibits the invasion and migration ability, so that the Act-V has wide application scenarios.

The application belongs to the field of biomedical technology, and provides application of POFUT1 as an esophageal squamous carcinoma diagnosis marker, drug screening and prognosis evaluation reagent. The POFUT1 protein or POFUT1 gene is specifically expressed in esophageal squamous carcinoma tissue, and the expression level is up-regulated. The reagent is for quantitatively detecting the expression amount of the POFUT1 protein or POFUT1 gene in the cytoplasm of a sample cell. As a key enzyme in the O-fucosylation modification process, POFUT1 has been proved to play an important role in the development of various cancers. The present research aims to determine the role of POFUT1 in esophageal squamous carcinoma and the mechanism of the O-fucosylation modification of proteins mediated by POFUT1 on the invasion and migration of esophageal squamous carcinoma.

The application discloses a kind of drug composition for pancreatic cancer liver metastasis under the background of metabolism-related fatty liver disease and preparation method and application thereof, the drug composition is with double-layer fat molecule spherical liposome as carrier, photosensitizer is loaded in the bilayer of liposome, chemotherapeutic drug gemcitabine is loaded in the cavity of liposome, gene therapy drug SiRNA CD44 is adsorbed on the surface of liposome.The GIR-Lip of the application can realize controllable killing and immune activation of tumor under laser irradiation, efficiently silence the high invasion and migration ability of CD44 tumor cells, combined with the first-line chemotherapeutic drug gemcitabine for pancreatic cancer, can ensure the combined effect, make up the drug resistance and curative effect loss caused by long-term use of gemcitabine.

The application discloses application of a STAT3 inhibitor combined with oxaliplatin in preparation of a drug for treating solid tumors with p-STAT3 activation or p-STAT3 low expression. The solid tumor with p-STAT3 activation is sensitive colorectal cancer. The solid tumor with p-STAT3 low expression is oxaliplatin-resistant colorectal cancer. The combination of the STAT3 inhibitor and the oxaliplatin has a good synergistic effect on the treatment of the colorectal cancer with p-STAT3 activation. Meanwhile, the combination of the STAT3 inhibitor and the oxaliplatin can increase the sensitivity of the colorectal cancer with p-STAT3 low expression to the oxaliplatin, enhance the role of the oxaliplatin in inhibiting the proliferation, invasion and migration of the CRC, obviously inhibit the growth rate of the CRC tumor in the body, and has a good synergistic effect on the colorectal cancer with p-STAT3 low expression and oxaliplatin resistance.

The application provides a Chinese lung large cell neuroendocrine carcinoma cell line with high lymph node metastasis potential and an application, and the preservation number of the cell line is CCTCC NO: C2024277. The cell line of the application is a lung large cell neuroendocrine carcinoma cell line which is rare in the histopathological type of lung cancer, has no homology with any human lung cancer cell line of other histopathological types, and has an abnormal karyotype. The cell line of the application can be continuously subcultured in vitro while keeping the biological characteristics of lung large cell neuroendocrine carcinoma tumor cells unchanged; has an in-vitro unlimited proliferation capacity, a good invasion and migration capacity, can induce subcutaneous tumor formation in mice, has a strong popliteal lymph node metastasis capacity in mice, and is suitable for being used as an in-vitro cell platform and an animal model cell line for researching the molecular mechanism of the occurrence, development and metastasis of the rare lung large cell neuroendocrine carcinoma and related diagnosis, treatment and drug research.

The invention discloses application of a pharmaceutical composition in preparation of a medicine for inhibiting liver cancer cell proliferation, and relates to the technical field of medicines. The pharmaceutical composition provided by the invention is a mixture of a flos carthami extract and a fructus gardeniae extract, wherein the mass ratio of the flos carthami extract to the fructus gardeniae extract is (1-2): (1-6). The safflower extract and the gardenia extract are found to be capable of remarkably inhibiting S100A6 protein expression, inhibiting hepatoma carcinoma cell Huh7 cell proliferation, inhibiting hepatoma carcinoma cell Huh7 cell cloning, inhibiting Huh7 cell proliferation genes, promoting expression of cancer suppressor genes, inhibiting Huh7 cell migration and inhibiting Huh7 cell invasion and migration related gene expression. New theoretical basis and experimental evidence are provided for application of traditional Chinese medicine in the field of liver cancer treatment, and an important guiding direction is provided for follow-up development of novel anti-liver cancer drugs based on flos carthami and fructus gardeniae.

The application belongs to the technical field of biological medicine, and discloses application of a miRNA-5134-5p inhibitor in preparation of an anti-breast cancer drug, wherein the miRNA-5134-5p inhibitor can effectively inhibit the invasion and migration ability of breast cancer cells, and has a significant anti-breast cancer effect. The application further provides a nucleotide sequence of the miRNA-5134-5p inhibitor, a probe sequence for detecting the expression level of miRNA-5134-5p, an anti-breast cancer small molecule drug, and a kit for evaluating the malignancy degree of breast cancer. Experiments prove that the miRNA-5134-5p inhibitor can significantly inhibit the malignant phenotype of breast cancer cells, and has potential clinical application value. The application provides a new target and strategy for the treatment of breast cancer, and has important clinical development and application prospects.

The invention belongs to the technical field of biological medicines, and discloses MMP12 as a biological marker for cervical cancer and precancerous lesions of cervical cancer and application of the MMP12 in order to solve the problem that a TIME change mechanism is still unclear in the progress process of cervical cancer at present. According to the application disclosed by the invention, the increase of MMP12 positive macrophages along with the progress of the cervical disease is determined for the first time, the MMP12 protein secreted by the MMP12 positive macrophages is a specific molecular characteristic of the progress of the cervical disease, and a new basis is provided for accurate diagnosis and treatment. Through multi-omics analysis and in-vivo and in-vitro functional experiments, it is proved that the MMP12 protein can drive growth, invasion and migration of cervical cancer tumors and shape an immunosuppression microenvironment, and the MMP12 protein is a treatment target with great potential. The effect of the MMP12 inhibitor is verified in an in-vivo and in-vitro model for the first time, and an experimental basis is provided for a treatment strategy of cervical cancer and precancerous lesions of cervical cancer.